Independently, RASSF1A has been extensively validated as a tumour suppressor in lung cancer where promoter methylation‐associated gene silencing correlates with poor progression and overall survival (Burbee et al, 2001; Lee et al, 2001; Neyaz et al, 2008; Pallarés et al, 2008; Grawenda & O'Neill, 2015). This evidence concerns the gene RASSF1 and neoplasm.